E7386 enhances lenvatinib’s antitumor activity in preclinical models and human hepatocellular carcinoma.

To study the antitumor and antiangiogenic activity of combining E7386 (an oral protein-protein interaction inhibitor targeting CREB-binding protein (CBP)/β-catenin) with lenvatinib and explore a novel mechanism of action of E7386 that boosts antitumor response. We transcriptomically profiled four HCC cell lines treated with DMSO or E7386 We transcriptomically profiled HCCs obtained from genetically engineered mouse models overexpressing MYC-lucOS;CTNNB1 and treated with Vehicle, E7386, Lenvatinib or E7386+Lenvatinib